

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

Silver State Scripts Board

Meeting Minutes

Date of Meeting: Thursday, September 23, 2021, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record	Notes																											
Closed Executive Session																													
Financial Review of Drug Classes with Proposed Changes	<p>Chairman Decerbo called the meeting to order at 1:00 PM on September 23, 2021.</p> <p>Roll was taken by Chairman Decerbo.</p> <table border="0" data-bbox="661 1055 1396 1416"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>The DHCFP Staff Present were as follows:</p> <p>Olsen, David, Social Services Chief III</p> <p>Gudino, Antonio, Social Services Program Specialist III</p> <p>Flowers, Ellen, Program Officer I</p> <p>Lither, Gabriel, Senior Deputy Attorney General (SDAG)</p>
	Present	Absent																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes
	<p>A quorum was present.</p> <p>Chairman Decerbo directed Kevin Whittington to proceed with the Financial Review of Drugs classes with proposed changes up for review during the Third Quarter/Annual 2021 Silver State Scripts Board meeting.</p> <p>Mr. Whittington reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside of this closed session of the Silver States Scripts Board meeting.</p> <p>Mr. Whittington presented the Financial Review of the Biologic Response Modifiers – Multiple Sclerosis Agents, Oral class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Cardiovascular Agents – Antilipemics – HMG-CoA Reductase Inhibitors (Statins) class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Dermatological Agents – Topical Antineoplastics – Topical Retinoids class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Psychotropic Agents – ADHD Agents class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Psychotropic Agents – Psychostimulants – Narcolepsy Agents class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Respiratory Agents – Short-Acting/Rescue Therapy class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Cardiovascular Agents – Antilipemics – Bile Acid Sequestrants class noting the products with proposed changes in PDL status.</p>	<p>Gainwell Technologies Staff Present were as follows: Leid, Jovanna, Pharm.D.</p> <p>OptumRx Staff Present were as follows: Whittington, Kevin, R.Ph. Kiriakopoulos, Amanda, Pharm.D. LeCheminant, Jill, Pharm.D. Chien, Michael, Pharm.D. Earnest, Rob, R.Ph., J.D. Piccirilli, Annette</p>

Agenda Item	Record	Notes
	<p>Mr. Whittington presented the Financial Review of the Anti-infective Agents – Aminoglycosides – Inhaled Aminoglycosides class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Biologic Response Modifiers – Immunomodulators – Targeted Immunomodulators class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Biologic Response Modifiers – Multiple Sclerosis Agents, Injectable class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Dermatological Agents – Topical Analgesics class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Gastrointestinal Agents – Gastrointestinal Enzymes class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Hormones and Hormone Modifiers – Antidiabetic Agents – Incretin Mimetics Agents class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Hormones and Hormone Modifiers – Antidiabetic Agents – Insulins (Vials, Pens and Inhaled) class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Musculoskeletal Agents – Antigout Agents class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Neurological Agents – Antiparkinsonian Agents – Dopamine Precursors class noting the products with proposed changes in PDL status.</p>	

Agenda Item	Record	Notes																											
	<p>Mr. Whittington presented the Financial Review of the Neurological Agents – Anti-Migraine Agents – Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Neurological Agents – Anti-Migraine Agents – Serotonin Receptor Agonists class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Ophthalmic Agents – Ophthalmic Antihistamines class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Respiratory Agents – Long-Acting/Maintenance Therapy class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington concluded the financial reviews and Chairman Decerbo directed the Board members to transition to the open session of the Silver States Scripts Board Meeting.</p>																												
Open Public Meeting																													
1. Call to Order and Roll Call	<p>Chairman Decerbo called the meeting to order at 2:25 PM on September 23, 2021.</p> <p>Roll was taken by Chairman Decerbo.</p> <table data-bbox="651 1015 1396 1388"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>The DHCFP Staff Present were as follows: Olsen, David, Social Services Chief III Gudino, Antonio, Social Services Program Specialist III Flowers, Ellen, Program Officer I Lither, Gabriel, SDAG</p> <p>Gainwell Technologies Staff Present were as follows: Leid, Jovanna, Pharm.D.</p>
	Present	Absent																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes
	A quorum was present.	<p>OptumRx Staff Present were as follows: LeCheminant, Jill, Pharm.D. Kiriakopoulos, Amanda, Pharm.D. Whittington, Kevin, R.Ph. Piccirilli, Annette Medina, Daniel Hansen, Sean Lee, Cara, Pharm.D. Chien, Michael, Pharm.D. Earnest, Rob, R.Ph., J.D.</p> <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity and in the absence of a sign-in sheet the accuracy of the attendee list is not assured.</p>
2. Public Comment on Any Matter on the Agenda.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>	
3. Administrative		
a. For Possible Action: Review and Approve Meeting Minutes from July 29, 2021.	<p>No corrections were offered.</p> <p>The minutes were approved by unanimous consent.</p>	

Agenda Item	Record	Notes
<p>b. Status Update by the DHCFP.</p>	<p>Chief David Olsen discussed the following dates for the upcoming Silver States Scripts Board meetings in the calendar year 2022. March 24, 2022, June 23, 2022, September 22, 2022, and December 15, 2022. Of the currently scheduled dates, the first two meetings have been posted online. Nevada Medicaid established contracts with managed care organizations, including a new managed care organization Molina which will begin starting January 1, 2022. Chief Olsen reviewed legislative updates, including Assembly Bill 177 that requires pharmacies to provide information regarding a prescription in languages other than English. Chief Olsen noted that the Board of Pharmacy is working on adopting the regulations. He covered Assembly Bill 178 that addresses early prescription renewals by pharmacists due to natural disasters effective earlier this month. Chief Olsen also provided information regarding the creation of a new provider type for pharmacists along with Senate Bill 190 that allows pharmacists to prescribe self-administered hormonal contraceptives and Senate Bill 325 which permits pharmacists to prescribe drugs to prevent the acquisition of human immunodeficiency virus (HIV) and to perform certain laboratory tests related to HIV testing. The public hearing for the State Plan Amendment for the new provider type is set for Tuesday, September 28 at 9 am to discuss the new provider type and pharmacist’s enrollment. All of these are scheduled for implementation on January 1, 2022. He commented that for any information on public meetings to see the public notices website for additional information. Chief Olsen announced that Magellan Medicaid Administration will start on July 1, 2022, as Nevada’s new pharmacy benefit manager (PBM). He noted that Magellan will begin facilitating the Silver State Scripts Board meetings at that time. Dr. Tina Hawkins from Magellan was present at the meeting to introduce herself and the team members. She commented that they were joining today to listen to the current process of meetings.</p> <p>Antonio Gudino announced that due to high levels of respiratory syncytial virus (RSV), Nevada Medicaid has extended the season beginning September 1, 2021, through March 31, 2022. He noted this is consistent with the</p>	<p>Referenced web addresses:</p> <p>The Nevada Department of Health and Human Services, Division of Health Care Financing and Policy Provider Portal. https://www.medicaid.nv.gov/</p> <p>The Division of Health Care Financing and Policy http://dhcftp.nv.gov/</p>

Agenda Item	Record	Notes
	guidance of the AAP. RSV activity will continue to be monitored to determine if season length should be extended.	
4. Established Drug Classes Being Reviewed Due to the Release of New Drugs		
a. For Possible Action: Discussion and possible adoption of Biological Response Modifiers – Multiple Sclerosis Agents, Oral.		
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was made by Sophia Yun, a pharmacist with Janssen Scientific Affairs. She provided clinical information regarding Ponvory. She noted that patients using this agent would not require the four-hour first dose monitoring. Ms. Yun provided indication information, efficacy, and safety data from Phase III clinical trials when compared to Aubagio. She noted superior efficacy when compared to Aubagio. Ms. Yun requested that Ponvory be added to the preferred drug list.</p> <p>Comment was provided by KayOnda Bayo from Bristol Myers Squibb representing Zeposia. Ms. Bayo provided indications for Zeposia and discussed clinical trials evaluating its safety and efficacy. She noted comparator studies with Avonex. Ms. Bayo requested that Zeposia be added to the formulary.</p>	
ii. Drug class review presentation by OptumRx.	Dr. LeCheminant discussed the new product, Ponvory, the mechanism of action, indication, administration, and clinical trial demonstrating efficacy. She noted its significant reduction in annualized relapse rate and MRI endpoints when compared with Aubagio in a Phase 3 study.	

Agenda Item	Record	Notes																								
	Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.																									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 527 1501 763"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended adding Ponvory as non-preferred.																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward moved to accept the proposed changes.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 1096 1501 1336"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
b. For Possible Action: Discussion and possible																										

Agenda Item	Record	Notes																								
<p>adoption of Cardiovascular Agents – Antilipemics – HMG-CoA Reductase Inhibitors (Statins)</p>																										
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																									
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant cited that this class is in the new drug sections because there was a new agent in the class; however, it is not yet part of the Medicaid Drug Rebate Program and will not be a part of the meeting today.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Khurana moved to accept the list is clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 954 1501 1193"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. LeCheminant recommended the Board move Vytorin to non-preferred and generic ezetimibe/simvastatin to preferred.</p>																									
<p>v. Discussion by Board and action</p>	<p>Board Member Ward moved to accept the proposed updates as presented.</p>																									

Agenda Item	Record	Notes																								
<p>by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 349 1501 581"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>c. For Possible Action: Discussion and possible adoption of Dermatological Agents – Topical Antineoplastics – Topical Retinoids.</p>																										
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																									
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant discussed the new formulation of tazarotene 0.045% lotion available as Arazlo. She summarized noted indications.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1347 1501 1421"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

Agenda Item	Record	Notes																								
	<p>Crumby, Mark, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Hautekeet, Mike, R.Ph <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Khurana, Sapandeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>																									
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. LeCheminant recommended Arazlo be added to the PDL as non-preferred and that Epiduo is moved to preferred.</p>																									
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Ward moved to accept the recommendation.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 727 1501 971"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>d. For Possible Action: Discussion and possible adoption of Psychotropic Agents – ADHD Agents.</p>																										
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was made by Justin Barnes, a medical science liaison with Ironshore Pharmaceuticals, regarding Jornay PM. Dr. Barnes discussed the differences of Jornay PM with other long-acting stimulants. He noted that there is no immediate release component to Jornay PM. Dr. Barnes</p>																									

Agenda Item	Record	Notes																								
	<p>commented on administration times, clinical efficacy, and safety. He requested that Jornay PM be maintained as a preferred agent on the PDL.</p> <p>Board Member Ward requested that in the interest of time that if no changes were being recommended to a preferred product to withhold comment at this time. Chairman Decerbo notified those in attendance how the slides are reviewed so that people wishing to provide comments can understand their product's status as preferred or non-preferred and what is being recommended.</p>																									
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant discussed Qelbree, a new product within this class. She discussed the mechanism of action, clinical studies, and other available agents in the class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Ward moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="651 987 1501 1230"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. LeCheminant recommended adding Qelbree as non-preferred, to move atomoxetine to preferred status and Strattera to non-preferred status.</p>																									

Agenda Item	Record	Notes																								
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Khurana moved to add Qelbree to preferred.</p> <p>Chairman Decerbo seconded the motion.</p> <p>Board Member Khurana stated that having another non-stimulant option available to patients with ADHD is needed. He noted concerns with stimulant options with aggression, irritability, and substance use disorder. He commented that atomoxetine was the only preferred non-stimulant option.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 630 1512 873"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Board Member Khurana inquired about the use of the brand Strattera agent and if members could be grandfathered for use. Dr. LeCheminant commented that the preference would be for members to switch to the preferred generic agent, but that grandfathering could be put in place.</p> <p>Board Member Khurana moved to maintain brand Strattera as preferred with atomoxetine as preferred.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>Board Member Ward asked if Board Member Khurana was concerned about patients preferring the brand over the generic. Board Member Khurana commented on his concerns requiring failure with the generic and having to proceed through the various steps to obtain approval</p>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

Agenda Item	Record	Notes																																																
	<p>through prior authorization for the brand product. Board Member Hautekeet noted that prescribers prefer to maintain patients on the brand product for certain agents. He notes that Strattera is one such product and his opinion that patients should be able to be maintained on whichever agent they start on.</p> <p>A vote was held:</p> <table data-bbox="674 513 1524 756"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Board Member Ward moved to maintain all other recommendations to this class on the PDL as presented.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="674 1040 1524 1284"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																															
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
	Yes	No	Abst.																																															
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
<p>e. For Possible Action: Discussion and possible adoption of Psychotropic</p>																																																		

Agenda Item	Record	Notes																								
Agents – Narcolepsy Agents.																										
i. Public comment.	<p>Dr. LeCheminant referenced submitted written public comment that was previously provided to the Board. She noted in the interest of time, she would not be reviewing individually during the meeting but that the Board had these comments prior to the meeting for their review.</p> <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Deb Profant regarding Xywav. She provided new indications, dosing, and sodium intake. She provided clinical efficacy and safety information. Ms. Profant provided information on the REMS program for Xywav. She requested access to Xywav, similar to Xyrem.</p>																									
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed Xywav. She cited indications, efficacy, and that like Xyrem has less sodium content leading to favorability in narcolepsy patients with comorbid conditions such as hypertension and heart failure.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 1161 1501 1408"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

Agenda Item	Record	Notes																								
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended adding Xywav to non-preferred and moving Wakix and armodafinil to non-preferred. Brand Nuvigil would be maintained as preferred.																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Khurana moved to maintain Wakix as preferred and accept all other recommendations as presented.</p> <p>Chairman Decerbo seconded the motion.</p> <p>Board Member Khurana commented that the dopamine pathway for treatment could present challenges. As Wakix has a different mechanism of action, it permits the usage of a different type of agent as preferred. Chairman Decerbo noted that during the closed session, it did appear that it was being used judiciously. Board Member Ward inquired about the decision pathway between sodium oxybate and Wakix. Board Member Khurana noted that maintaining Wakix on the preferred side would provide a non-controlled substance as preferred. Board Member Ward noted that patients are also utilizing sodium oxybate.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 941 1501 1193"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
f. For Possible Action: Discussion and possible adoption of Respiratory Agents, Short-Acting/Rescue Therapy.																										

Agenda Item	Record	Notes																								
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																									
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed indications of Proair Digihaler and its' built-in sensors to detect use and inspiratory flow.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 771 1501 1015"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. LeCheminant recommended Proair Digihaler be added as non-preferred.</p>																									

Agenda Item	Record	Notes																								
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board member Ward motioned to accept the changes as presented.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 418 1501 657"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
5. Classes Being Reviewed Due to New Generics																										
a. For Possible Action: Discussion and possible adoption of Cardiovascular Agents – Antilipemics – Bile Acid Sequestrants																										
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																									
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed Welchol. Generic colesevelam is available.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
iii. Discussion by Board and action by Board to	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p>																									

Agenda Item	Record	Notes																								
<p>approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="661 381 1501 621"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. LeCheminant recommended adding colesevelam to non-preferred.</p>																									
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Khurana moved to accept the recommendation.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="661 954 1501 1195"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>6. Established drug classes</p>																										
<p>a. For Possible Action: Discussion and possible adoption of Anti-infective Agents, Aminoglycosides, Inhaled Aminoglycosides.</p>																										

Agenda Item	Record	Notes																								
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																									
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed available generic agents.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Ward moved to accept the class as clinically and therapeutically equivalent.</p> <p>Chairman Decerbo seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 738 1501 980"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. LeCheminant recommended moving tobramycin nebulizer 300mg/4mL to non-preferred.</p>																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward moved to accept the recommendation.</p> <p>Chairman Decerbo seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1307 1501 1427"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>													
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

Agenda Item	Record	Notes												
	<table border="0"> <tr> <td data-bbox="663 240 1171 272">Hautekeet, Mike, R.Ph</td> <td data-bbox="1182 240 1213 272"><input checked="" type="checkbox"/></td> <td data-bbox="1308 240 1339 272"><input type="checkbox"/></td> <td data-bbox="1434 240 1465 272"><input type="checkbox"/></td> </tr> <tr> <td data-bbox="663 280 1171 313">Khurana, Sapandeep, MD</td> <td data-bbox="1182 280 1213 313"><input checked="" type="checkbox"/></td> <td data-bbox="1308 280 1339 313"><input type="checkbox"/></td> <td data-bbox="1434 280 1465 313"><input type="checkbox"/></td> </tr> <tr> <td data-bbox="663 321 1171 354">Ward, Kate, Pharm.D.</td> <td data-bbox="1182 321 1213 354"><input checked="" type="checkbox"/></td> <td data-bbox="1308 321 1339 354"><input type="checkbox"/></td> <td data-bbox="1434 321 1465 354"><input type="checkbox"/></td> </tr> </table>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
<p>b. For Possible Action: Discussion and possible adoption of Biologic Response Modifiers – Targeted Immunomodulators.</p>														
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Ben Droese, a pharmacist with Amgen Medical Affairs, regarding rituximab-arrx and its' newly assigned Q code effective July 1, 2021, of Q5123.</p> <p>Melissa Sommers, a medical science liaison with Novartis, provided public comment regarding Cosentyx. She provided indication information, clinical trial safety, and efficacy information. Ms. Sommers requested that Cosentyx be moved back to preferred status.</p>													
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant discussed Enspryng. She noted that this is a new agent in the class that became available after the agenda was already established. She discussed the mechanism of action, indication, efficacy studies, and other agents available in the class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>													
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p>													

Agenda Item	Record	Notes																								
	<table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended adding Enspryng as non-preferred and moving Cosentyx, Inflectra, Renflexis, Stelara, and Xeljanz XR to non-preferred.																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward noted the multiple indications for each of the agents. She moved to permit continued use of agents of therapy, moving from preferred to non-preferred indefinitely (Cosentyx, Stelara, Xeljanz XR).</p> <p>Board Member Hautekeet seconded the motion.</p> <p>Chairman Decerbo noted that he is not fully supportive of moving Stelara and Cosentyx to non-preferred. He did not ask to change any motion but wanted to make those aware of his thoughts.</p> <p>A vote was held:</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table> <p>Chairman Decerbo motioned to have Cosentyx and Stelara maintained as preferred and Xeljanz XR moved to non-preferred.</p>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																							

Agenda Item	Record	Notes																																																
	<p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="674 358 1514 597"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Board Member Ward motioned to maintain Inflectra and Renflexis as preferred. She noted potential access issues with formularies at different infusion centers.</p> <p>Chairperson Decerbo seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="674 943 1514 1182"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Board Member Khurana inquired if there was a need to grandfather utilizers of Xeljanz XR. Chairman Decerbo did not see a need to grandfather utilizers of this product but would welcome a motion if others felt differently.</p>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																															
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
	Yes	No	Abst.																																															
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																															

Agenda Item	Record	Notes																								
	<p>Board Member Khurana motioned to accept all other recommendations to this class as presented.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="674 456 1514 696"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandee, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandee, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandee, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>c. For Possible Action: Discussion and possible adoption of Biologic Response Modifiers – Multiple Sclerosis Agents, Injectable</p>																										
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Melissa Sommers from Novartis for Kesimpta. She provided agent indications and requested that the product be added as preferred to the PDL. She noted administration of Kesimpta along with clinical trial efficacy.</p>																									
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant discussed current generic availability.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve</p>	<p>Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent.</p>																									

Agenda Item	Record	Notes																								
<p>clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 349 1501 581"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. LeCheminant recommended moving Rebif to non-preferred.</p>																									
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo noted that interferon utilization is low. He noted that the two beta-1a products are not interchangeable. Chairman Decerbo stated that it would be reasonable to grandfather Rebif utilizers.</p> <p>Chairman Decerbo motioned that current utilizers of Rebif be grandfathered when moved to non-preferred.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>Board Member Ward asked that Kesimpta, Lemtrada, and Ocrevus be reviewed for access regarding PA criteria. Dr. LeCheminant noted that she would review these criteria with the DUR Board.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1242 1501 1390"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>									
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

Agenda Item	Record	Notes																
	Khurana, Sapandeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>																	
d. For Possible Action: Discussion and possible adoption of Dermatological Agents – Topical Analgesics.																		
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Kalpana Patel, PharmD and VP of Medical Affairs of Scilex Pharmaceuticals, representing ZTLido. Dr. Patel provided indications for ZTLido, disease state background, mechanism of action, and clinical efficacy studies. She noted adverse events with lidocaine patches and patch adhesion studies when compared to Lidoderm and generic patches. Dr. Patel requested ZTLido to be moved to preferred on the PDL.</p>																	
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed a new product, Lenzapro. She noted the formulation of lidocaine 4% with a 4% menthol OTC patch. She reviewed the generic options within this class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="661 1255 1501 1409"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.															
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															

Agenda Item	Record	Notes																								
	Khurana, Sapandeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>																									
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended adding Lenzapro to non-preferred and moving Lidocaine 5% patch to non-preferred. Lidoderm was recommended to move to preferred.																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward moved to accept the recommendation.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>Board Member Ward noted the substantial number of claims due to non-preferred agents and wanted clarification of the use of the non-preferred claims (generic diclofenac gel and ZTLido). Dr. LeCheminant noted potential dual coverage with a different insurance that requires the generic version. Mr. Whittington also noted the availability of some of the branded products leading to increased utilization of the generic non-preferred agents.</p> <p>A vote was held:</p> <table data-bbox="653 894 1503 1138"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
e. For Possible Action: Discussion and possible adoption of Gastrointestinal Agents – Gastrointestinal Enzymes.																										
i. Public comment.	Telephonic and web comment was called for, and the phone lines were opened.																									

Agenda Item	Record	Notes																								
	No public comment was offered.																									
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed current generic availability within this drug class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Ward moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="651 633 1501 868"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended moving Pancreaze to preferred.																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairperson Decerbo moved to accept the recommendation.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="651 1209 1501 1396"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>					
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

Agenda Item	Record	Notes
	Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	
f. For Possible Action: Discussion and possible adoption of Hormone and Hormone Modifiers – Antidiabetic Agents – Incretin Mimetics Agents.		
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Dr. Dewan regarding glucagon and GLP1 agents. Dr. Dewan requested that no PA be required for patients exhibiting signs of insulin resistance to prevent movement to Type 2 Diabetes. Dr. Dewan also requested that pre-formulated glucagon agents be added as preferred for ease of administration with different caregivers. He noted phone calls he receives in the ER due to caregivers not being able to administer the current preferred glucagon formulations.</p> <p>Chairman Decerbo noted that requests regarding PA criteria for the GLP1 would be best served with the DUR Board as they determine the PA criteria. He also noted that glucagon is not on the agenda today for review but that this class could be reviewed in December. Chairman Decerbo encouraged Dr. Dewan to return at that time to discuss these classes.</p> <p>Gabriel Lither noted that all drugs could have action reviewed since it is the annual meeting. Chairman Decerbo deferred to the Board due to the lack of cost information previously reviewed. Board Member Ward agreed that a December agenda item would be more appropriate for a cost review.</p> <p>Dr. Dewan also requested that Rybelsus be added to preferred as an oral formulation due to potential patient needle phobia.</p> <p>Comment was provided by Justin Calecc with Novo Nordisk regarding Rybelsus. He noted that it is the first and only oral GLP1 agonist. Mr. Calecc</p>	

Agenda Item	Record	Notes																								
	<p>provided guideline information. He stated that it is the same molecule as the injectable Ozempic formulation. He specified that the safety profiles were similar between both agents. Mr. Calecc provided safety and efficacy clinical trial information.</p>																									
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant discussed indications and current generic availability within this drug class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 771 1501 1015"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. LeCheminant recommended moving Trulicity to non-preferred.</p>																									
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo moved to move Trulicity to non-preferred and Rybelsus to preferred.</p> <p>Board Member Ward seconded the motion.</p> <p>Board Member Ward asked if the DUR Board could address criteria regarding avoidance of injectable product if it were left as non-preferred.</p>																									

Agenda Item	Record	Notes																								
	<p>Dr. LeCheminant confirmed that it could be discussed with the DUR Board. Chairman Decerbo confirmed that these recommendations would apply to these products only and not for those that are utilized for weight loss only.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 418 1501 657"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>g. For Possible Action: Discussion and possible adoption of Hormone and Hormone Modifiers – Antidiabetic Agents – Insulins (Vials, Pens and Inhaled).</p>																										
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																									
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant discussed current generic availability within this drug class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p>																									

Agenda Item	Record	Notes																								
	<table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended moving Insulin aspart mix and insulin lispro mix to preferred.																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward moved to accept the recommendation.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
h. For Possible Action: Discussion and possible adoption of Musculoskeletal Agents – Antigout Agents																										
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																									

Agenda Item	Record	Notes																								
ii. Drug class review presentation by OptumRx.	Dr. LeCheminant discussed current generic availability within this drug class. Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.																									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent. Board Member Khurana seconded the motion. A vote was held: <table data-bbox="653 597 1503 837" style="margin-left: 40px;"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended moving febuxostat to non-preferred and Uloric to preferred.																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Ward moved to accept the recommendation. Board Member Crumby seconded the motion. A vote was held: <table data-bbox="653 1170 1503 1409" style="margin-left: 40px;"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

Agenda Item	Record	Notes																								
i. For Possible Action: Discussion and possible adoption of Neurological Agents – Antiparkinsonian Agents – Dopamine Precursors.																										
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Brian Wensel from Sunovian Pharmaceuticals regarding Kynmobi. Mr. Wensel provided information on current treatment options. He discussed the acute treatment of on/off episodes. Mr. Wensel discussed dosing, indication, tolerability, efficacy, and safety of Kynmobi. He requested that the Board review Kynmobi and add it to the PDL.</p>																									
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed current generic availability within this drug class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 1096 1501 1339"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for	Dr. LeCheminant recommended moving Stalevo to non-preferred and the generic, carbidopa/levodopa/entacapone to preferred.																									

Agenda Item	Record	Notes																								
PDL inclusion by OptumRx.																										
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward moved to accept the recommendation.</p> <p>Board Member Crumby seconded the motion.</p> <p>Chairman Decerbo asked if Kynmobi was placed somewhere else on the PDL. Dr. LeCheminant noted she believed it would fall under a different category and would bring back at the December meeting.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 634 1501 873"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
j. For Possible Action: Discussion and possible adoption of Anti-Migraine Agents – Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists.																										
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Dr. Medhi Ansarinia regarding the CGRP Receptor Antagonists. He noted that Ajovy is preferred and that in his experience as a headache specialist, he encounters less wear-off or increased headaches prior to the next dose. He asked that it remain as preferred.</p>																									

Agenda Item	Record	Notes																								
	<p>Comment was provided by Ben Droese with Amgen Medical Affairs. He appreciated the recommendation of Aimovig as preferred and asked for any questions.</p> <p>Ryan Norman gave back time and opened for any questions.</p>																									
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant discussed indications and those agents used for acute and preventative treatment. She noted Emgality is the only agent indicated for cluster headache treatment.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="653 846 1503 1084"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. LeCheminant recommended moving Aimovig to preferred and Ubrelvy to non-preferred.</p>																									
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Ward moved to accept the recommendation. Chairman Decerbo and Board Member Ward agreed that abortive options were still available on preferred.</p> <p>Board Member Crumby seconded the motion.</p>																									

Agenda Item	Record	Notes																								
	<p>A vote was held:</p> <table border="0" data-bbox="661 310 1501 550"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>k. For Possible Action: Discussion and possible adoption of Anti-Migraine Agents – Serotonin-Receptor Agonists</p>																										
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																									
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant noted generic agents available in this class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1245 1501 1390"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>									
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							

Agenda Item	Record	Notes																								
	Khurana, Sapandeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>																									
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended moving Frova, Relpax, and zolmitriptan nasal spray to preferred and Zomig nasal spray to non-preferred.																									
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairman Decerbo moved to accept the recommendation. Board Member Ward seconded the motion. A vote was held: <table data-bbox="653 646 1503 886" style="margin-left: 40px;"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
I. For Possible Action: Discussion and possible adoption of Ophthalmic Agents – Ophthalmic Antihistamines																										
i. Public comment.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was offered.																									
ii. Drug class review presentation by OptumRx.	Dr. LeCheminant noted generic agents available in this class. Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.																									
iii. Discussion by Board and action by Board to	Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.																									

Agenda Item	Record	Notes																								
<p>approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 381 1501 621"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. LeCheminant recommended moving azelastine, Lastacraft, and olopatadine to preferred and Pazeo to non-preferred.</p>																									
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Ward moved to accept the recommendation.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 950 1501 1195"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>m. For Possible Action: Discussion and possible adoption of Respiratory Agents – Long-Acting/Maintenance Therapy.</p>																										

Agenda Item	Record	Notes																								
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Dr. Tayo Fakunle for Alvesco. She provided indications, dosing, and clinical trial information regarding safety and efficacy for Alvesco. In addition, Dr. Fakunle provided tolerability and side effect information along with the mechanism of action. She asked that Alvesco be added to the PDL.</p>																									
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant noted generic agents available in this class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																									
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 883 1503 1125"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. LeCheminant recommended moving Asmanex and Bevespi to non-preferred.</p>																									
v. Discussion by Board and action by Board for approval of drugs	<p>Board Member Ward asked for the rationale for maintaining Tudorza as preferred on the PDL as a single agent when the combination agents were moved to non-preferred. Dr. LeCheminant mentioned that while she does not have cost information in front of her now, she did recall a financial</p>																									

Agenda Item	Record	Notes																								
<p>for inclusion on the PDL.</p>	<p>reason for leaving as preferred and maintaining as many agents as preferred as possible for additional options.</p> <p>Chairman Decerbo moved to accept the recommendation.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="659 526 1459 768"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>7. Drug Classes without Proposed Changes</p>																										
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Emily Smith from Zealand Pharma regarding glucagon products. She noted her appreciation for the opportunity to provide testimony in December for these agents.</p> <p>Melissa Sommers with Novartis provided public comment regarding Entresto. She noted updates to the label regarding reducing CV death and hospitalizations in patients with heart failure. She requested that Entresto be added as preferred and provided supporting clinical literature. Dr. LeCheminant noted that these criteria would be reviewed at the next DUR Board meeting. Mr. Whittington noted that Entresto is not currently a drug on the PDL and asked Gabriel Lither if it would be best to wait until December. Mr. Lither noted that it could be addressed today but would</p>																									










	<p>likely be best to wait until December. Dr. LeCheminant commented that she would bring these in December.</p> <p>Robert Rollins, a pediatric cardiologist, provided public comment regarding Hemangeol. He noted better compliance, no alcohol present, and a better flavoring for babies. He requested it to be added to preferred. Chairman Decerbo noted that pricing data for this product was previously reviewed. Board Member Ward asked if there were any established PA criteria for Hemangeol. Dr. LeCheminant confirmed there are no PA criteria. Chairman Decerbo commented that unless the Board felt differently, he was comfortable not making any changes at this time.</p>																									
<p>ii. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo moved to accept the remaining drug classes with no changes being accepted.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 808 1566 1052"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
<p>8. OptumRx Reports: New Drugs to Market and New Line Extensions</p>	<p>Dr. LeCheminant reviewed daridorexant, a new drug indicated for the treatment of narcolepsy that is expected to be approved in January. Dr. LeCheminant mentioned two drugs with new formulations, dextroamphetamine transdermal, and buprenorphine subcutaneous injection. She noted that generic Cayston is likely to be available in December.</p>																									
<p>9. Closing Discussion</p>																										
<p>a. Public comments on any subject.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p>																									

	No public comment was offered.	
b. Date and location of the next meeting.	Chairman Decerbo confirmed the next meeting is scheduled for December 9, 2021, and will be a hybrid meeting.	
c. Adjournment.	Chairman Decerbo adjourned the meeting at 4:54 PM.	

Attachment A – Members of the Public in Attendance

Abbott, Susan, Covis Pharma	Ferrolti, Joseph, Takeda	Reemts, Robert, UCB
Alegria, Veronica, DHCFP	Fox, Linda, DHHS	Ritter, Jean
Ansarinia, Dr. Mehdi	Gaon, Dominic, WellPoint	Roehr, Steven, Magellan
Appolonia, Patrick	Germain, Joe, Biogen	Rollins, Robert
Ashton, Elisa, Johnson & Johnson	Gorzynski, Andy	Roy, Melissa
Asokan, Vimal, Wellpoint	Groppenbacher, Shannon, Johnson & Johnson	Santarone, Christopher, Bristol Myers Squibb
Bailey, Alan, UCB	Hawkins, Tina, Magellan	Schillo, John, Lundbeck
Bala, Kaysen	Hill, Laura, AbbVie	Schlatter, David, Covis Pharma
Barnes, Justin, Ironshore Pharma	Howard, Kathleen, Scilex Pharma	Sebastian, Paul, Optum
Basset, Dylan, Pierre-Fabre	Kam, Calvin, WellPoint	Shurtleff, Madeline, Otsuka
Bayo, KayOnda, Bristol Myers Squibb	Kniffin, Jason	Smith, Emily, Zealand Pharma
Belz, Jeanette, Nbelz & Case	Large, David	Smith, Jason, Gilead
Bitton, Ryan, HPN	Legg, Jody, Mirum Pharma	Sommers, Melissa, Novartis
Bogard, Lisa, WellPoint	Lim, Luke, WellPoint	Springs, Tami, Pierre-Fabre
Booth, Robert	Lovan, Charlie, AbbVie	Stepien, Scott , Ispen
Calecc, Justin	Morgan, Derek, Ironshore Pharma	Walter, Lindsey, Novartis
Cameron, Stormy, Artia Solutions	Nguyen, Bao, Janus	Wensel, Brian, Sunovion
Camille, Kerr	Norman, Ryan	Yamashita, Kelvin
Chan, Betty, Gilead	Oliver, Carmen, Biohaven Pharma	Young, Sara, UCB
Chow, Ellen	Ou, Karen, Gilead	Yun, Sophia, Janus
Colabianchi, Jeana, Sunovion	Parsa, Pirooz, Bristol Myers Squibb	Zarob, Michael, Alkermes
Cooper, Christa	Patadia, Hiten, Otsuka	Zimmerman, David, Novo Nordisk
Cruz, Ashley, Carra NV	Patel, Kalpana, Scilex Pharma	
De Rosa, Regina, WellPoint	Pearce, Robert	Attendees with no last name available:
Droese, Ben, Amgen	Pericci, Michele, Scilex Pharma	Christa
Duke, Michelle	Phillips, Katherine, Jazz Pharma	Dewan
Dynak, Dawn, Gilead	Profant, Deb, Jazz Pharma	Jasi
Eldridge, Edward, Gilead	Quon, Warner, Idorsia	Kenneth
Fakunle, Tayo, Covis Pharma		Mike

Attachment B – Submitted Written Comment

-  Antipsychotic_1.pdf
-  Antipsychotic_2_Rexulti.pdf
-  Antipsychotic_3.pdf
-  Antipsychotic4.pdf
-  CGRP Ajovy 1.pdf
-  Hemangeol1.pdf
-  Ironshore JORNAY PM Medicaid Public Testimonial.pdf
-  State Formulary Review ZEGALOGUE (dasiglucagon) injection (002).pdf
-  Xywav Medicaid Testimony_Nevada_narcolepsy category_August 2021.pdf